Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03289741 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
A Phase 4 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
NCT03289741: Completed Phase 4 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03289741 is a Phase 4 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03289741, a Phase 4 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
Study Summary
This study is being done to evaluate differences in patient experience during treatment with octreotide LAR and lanreotide.
Interventions
- BEHAVIORAL Questionnaires
- DRUG Octreotide
- DRUG LAR Lanreotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2017-09-19 |
| Est. Completion | 2023-04-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03289741
The ClinicalTrials.gov registry entry for NCT03289741 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Questionnaires is the first listed.
NCT03289741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03289741 about?
NCT03289741 is a clinical study titled "A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide". This study is being done to evaluate differences in patient experience during treatment with octreotide LAR and lanreotide.
What is the current status of trial NCT03289741?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 2017-09-19. Estimated completion is 2023-04-10.
What interventions are being tested in trial NCT03289741?
The interventions under investigation include: Questionnaires (BEHAVIORAL), Octreotide (DRUG), LAR Lanreotide (DRUG).
Who is sponsoring clinical trial NCT03289741?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.